Haochen Xu1, Marwa T Thomas1, Dayeong Lee1, Matthew T Hirabayashi1, Jella A An2,3. 1. Mason Eye Institute, Department of Ophthalmology, University of Missouri-Columbia, Columbia, MO, USA. 2. Mason Eye Institute, Department of Ophthalmology, University of Missouri-Columbia, Columbia, MO, USA. jan22@jh.edu. 3. Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins Medicine, 6430 Rockledge Drive, Suite 600, Bethesda, MD, 20817, USA. jan22@jh.edu.
Abstract
PURPOSE: To compare the intraocular pressure (IOP)-lowering effects of netarsudil on goniotomy-treated eyes versus goniotomy-naïve control eyes. METHODS: Retrospective cohort study of 70 eyes from 49 adult glaucoma patients treated with netarsudil. Thirty-five eyes received sectoral goniotomy using Kahook Dual Blade (KDB) combined with cataract surgery with minimum of 3 months prior to netarsudil treatment. Thirty-five eyes in the control cohort received only cataract surgery prior to netarsudil. Primary outcome was treatment success, defined as ≥ 20% decrease in IOP at minimum 1 month follow-up. Secondary outcome measures included percent of IOP reduction, adverse effects of medication, medication discontinuation rate, and relationship between KDB goniotomy response and netarsudil response. RESULTS: Eighty-three percent of KDB-treated eyes achieved netarsudil treatment success compared to 54% of control eyes (P = .012). IOP reduction was 30.3 ± 16.2% (IQR 21-38%) in KDB-treated eyes and 19.4 ± 12.4% (IQR 9.2-30.8) in control eyes (P = .007). History of prior KDB increased the likelihood of success to netarsudil treatment compared to eyes without prior KDB, regardless of surgical response to KDB (odds ratio 4.51, 95% CI 1.34-15.14, P = .015). The overall rate of adverse effects of netarsudil was 42%, most commonly reported as conjunctival hyperemia, allergy, and blurred vision. CONCLUSIONS: Netarsudil had a greater IOP-lowering effect in eyes treated with prior goniotomy and may serve as a promising adjunctive ocular hypotensive agent to further reduce IOP in eyes with prior goniotomy.
PURPOSE: To compare the intraocular pressure (IOP)-lowering effects of netarsudil on goniotomy-treated eyes versus goniotomy-naïve control eyes. METHODS: Retrospective cohort study of 70 eyes from 49 adult glaucoma patients treated with netarsudil. Thirty-five eyes received sectoral goniotomy using Kahook Dual Blade (KDB) combined with cataract surgery with minimum of 3 months prior to netarsudil treatment. Thirty-five eyes in the control cohort received only cataract surgery prior to netarsudil. Primary outcome was treatment success, defined as ≥ 20% decrease in IOP at minimum 1 month follow-up. Secondary outcome measures included percent of IOP reduction, adverse effects of medication, medication discontinuation rate, and relationship between KDB goniotomy response and netarsudil response. RESULTS: Eighty-three percent of KDB-treated eyes achieved netarsudil treatment success compared to 54% of control eyes (P = .012). IOP reduction was 30.3 ± 16.2% (IQR 21-38%) in KDB-treated eyes and 19.4 ± 12.4% (IQR 9.2-30.8) in control eyes (P = .007). History of prior KDB increased the likelihood of success to netarsudil treatment compared to eyes without prior KDB, regardless of surgical response to KDB (odds ratio 4.51, 95% CI 1.34-15.14, P = .015). The overall rate of adverse effects of netarsudil was 42%, most commonly reported as conjunctival hyperemia, allergy, and blurred vision. CONCLUSIONS: Netarsudil had a greater IOP-lowering effect in eyes treated with prior goniotomy and may serve as a promising adjunctive ocular hypotensive agent to further reduce IOP in eyes with prior goniotomy.
Authors: Guorong Li; Dibyendu Mukherjee; Iris Navarro; Nicole E Ashpole; Joseph M Sherwood; Jinlong Chang; Darryl R Overby; Fan Yuan; Pedro Gonzalez; Casey C Kopczynski; Sina Farsiu; W Daniel Stamer Journal: Eur J Pharmacol Date: 2016-04-13 Impact factor: 4.432
Authors: Arash Kazemi; Jay W McLaren; Casey C Kopczynski; Theresa G Heah; Gary D Novack; Arthur J Sit Journal: J Ocul Pharmacol Ther Date: 2018-02-22 Impact factor: 2.671
Authors: Lauriane Salinas; Ankita Chaudhary; John P Berdahl; Gabriel S Lazcano-Gomez; Blake K Williamson; Syril K Dorairaj; Leonard K Seibold; Sanjay Smith; Ahmad A Aref; Jason K Darlington; Jesus Jimenez-Roman; Ahad Mahootchi; Mohamed Boucekine; Kaweh Mansouri Journal: J Glaucoma Date: 2018-10 Impact factor: 2.503
Authors: Albert S Khouri; Janet B Serle; Jason Bacharach; Dale W Usner; Richard A Lewis; Puiwah Braswell; Casey C Kopczynski; Theresa Heah Journal: Am J Ophthalmol Date: 2019-03-09 Impact factor: 5.258
Authors: Syril K Dorairaj; Leonard K Seibold; Nathan M Radcliffe; Ahmad A Aref; Jesús Jimenez-Román; Gabriel S Lazcano-Gomez; Jason K Darlington; Kaweh Mansouri; John P Berdahl Journal: Adv Ther Date: 2018-08-04 Impact factor: 3.845